In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Taiyen Biotech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

TWSE:1737 - Analysts future estimates and past financials data (TWD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
9/30/2024	3,220	298	229	531	N/A
6/30/2024	3,302	358	156	482	N/A
3/31/2024	3,357	297	93	442	N/A
12/31/2023	3,409	300	109	455	N/A
9/30/2023	3,486	389	20	332	N/A
6/30/2023	3,541	399	616	828	N/A
3/31/2023	3,555	408	527	774	N/A
12/31/2022	3,614	427	334	581	N/A
9/30/2022	3,969	419	734	1,014	N/A
6/30/2022	4,116	357	-142	289	N/A
3/31/2022	4,229	418	79	425	N/A
12/31/2021	4,096	393	209	600	N/A
9/30/2021	3,758	431	-204	200	N/A
6/30/2021	3,391	427	152	422	N/A
3/31/2021	3,196	402	101	280	N/A
12/31/2020	3,130	365	71	339	N/A
9/30/2020	3,008	318	160	409	N/A
6/30/2020	3,027	308	13	333	N/A
3/31/2020	2,955	316	61	399	N/A
12/31/2019	2,907	346	44	329	N/A
9/30/2019	2,905	335	45	351	N/A
6/30/2019	2,878	337	215	447	N/A
3/31/2019	2,996	460	245	483	N/A
12/31/2018	3,001	453	151	450	N/A
9/30/2018	2,933	452	53	390	N/A
6/30/2018	2,925	475	N/A	459	N/A
3/31/2018	2,783	375	N/A	395	N/A
12/31/2017	2,757	354	N/A	530	N/A
9/30/2017	2,749	357	N/A	556	N/A
6/30/2017	2,747	347	N/A	472	N/A
3/31/2017	2,782	349	N/A	581	N/A
12/31/2016	2,755	352	N/A	568	N/A
9/30/2016	2,762	317	N/A	581	N/A
6/30/2016	2,752	338	N/A	568	N/A
3/31/2016	2,751	289	N/A	471	N/A
12/31/2015	2,761	269	N/A	384	N/A
9/30/2015	2,722	289	N/A	402	N/A
6/30/2015	2,669	223	N/A	348	N/A
3/31/2015	2,608	186	N/A	370	N/A
12/31/2014	2,576	214	N/A	371	N/A
9/30/2014	2,566	210	N/A	348	N/A
6/30/2014	2,507	181	N/A	287	N/A
3/31/2014	2,475	161	N/A	207	N/A
12/31/2013	2,409	126	N/A	203	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 1737's forecast earnings growth is above the savings rate (1.1%).

Earnings vs Market: Insufficient data to determine if 1737's earnings are forecast to grow faster than the TW market

High Growth Earnings: Insufficient data to determine if 1737's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 1737's revenue is forecast to grow faster than the TW market.

High Growth Revenue: Insufficient data to determine if 1737's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 1737's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/18 21:59
End of Day Share Price	2024/12/18 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Taiyen Biotech Co., Ltd. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
null null	E.Sun Securities Investment Consulting Co. Ltd.
Titan Horng	IBTS Investment Consulting Co., Ltd.
Zhennan Lee	Jih Sun Securities Investment Consulting Co., Ltd.

Taiyen Biotech Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

Third quarter 2024 earnings released: EPS: NT$0.45 (vs NT$0.76 in 3Q 2023)

Taiyen Biotech Co., Ltd. Announces the Appointment of Ting, Yen-Che as Institutional Director

Upcoming dividend of NT$1.20 per share

Taiyen Biotech's (TWSE:1737) Dividend Will Be Reduced To NT$1.20

Dividend reduced to NT$1.20

Taiyen Biotech Co., Ltd. to Report Q2, 2024 Results on Jul 29, 2024

High number of new directors

Taiyen Biotech Co., Ltd. Announces the Appointment of Ho, An-Ping as Institutional Director

Investors Can Find Comfort In Taiyen Biotech's (TWSE:1737) Earnings Quality

First quarter 2024 earnings released: EPS: NT$0.52 (vs NT$0.54 in 1Q 2023)

Full year 2023 earnings released: EPS: NT$1.50 (vs NT$2.13 in FY 2022)

Taiyen Biotech Co., Ltd., Annual General Meeting, Jun 21, 2024

Upcoming dividend of NT$1.50 per share at 4.4% yield

Second quarter 2023 earnings released: EPS: NT$0.19 (vs NT$0.23 in 2Q 2022)

Taiyen Biotech Co., Ltd. Approves Cash Dividend, Payable on September 19, 2023

High number of new directors

Taiyen Biotech Co., Ltd. Announces Director Changes

New major risk - Revenue and earnings growth

Taiyen Greenenergy Co., LTD. Announces Resignation of Yi-Hui Tsai as Director of Financial& Accounting, Effective June 20, 2023

Full year 2022 earnings released: EPS: NT$2.13 (vs NT$1.97 in FY 2021)

Full year 2022 earnings released: EPS: NT$2.13 (vs NT$1.97 in FY 2021)

Taiyen Biotech Co., Ltd. Change of the Spokesperson

Third quarter 2022 earnings released: EPS: NT$0.81 (vs NT$0.50 in 3Q 2021)

Taiyen Biotech Co., Ltd. Replaces Wang, Ching-Sen with Chuang, Mei-Yu as Chief Internal Auditor, with Effect from November 16, 2022

Upcoming dividend of NT$1.50 per share

Second quarter 2022 earnings released: EPS: NT$0.23 (vs NT$0.53 in 2Q 2021)

Taiyen Biotech Co., Ltd. Announces Cash Dividend, Payable on September 20, 2022

Taiyen Biotech Co., Ltd. Announces Executive Changes

First quarter 2022 earnings released: EPS: NT$0.64 (vs NT$0.51 in 1Q 2021)

Less than half of directors are independent

Third quarter 2021 earnings released: EPS NT$0.50 (vs NT$0.48 in 3Q 2020)

Upcoming dividend of NT$1.35 per share

Second quarter 2021 earnings released: EPS NT$0.53 (vs NT$0.41 in 2Q 2020)

First quarter 2021 earnings released: EPS NT$0.51 (vs NT$0.33 in 1Q 2020)

Taiyen Biotech (TPE:1737) Has A Pretty Healthy Balance Sheet

Taiyen Biotech's (TPE:1737) Returns On Capital Are Heading Higher

Full year 2020 earnings released: EPS NT$1.83 (vs NT$1.73 in FY 2019)

A Look At The Intrinsic Value Of Taiyen Biotech Co., Ltd. (TPE:1737)

Is Taiyen Biotech Co., Ltd. (TPE:1737) Popular Amongst Institutions?

Taiyen Biotech Co., Ltd. (TPE:1737) Stock's On A Decline: Are Poor Fundamentals The Cause?

New 90-day low: NT$31.85

Taiyen Biotech Co., Ltd. (TPE:1737) Investors Should Think About This Before Buying It For Its Dividend

New 90-day low: NT$32.05

Taiyen Biotech (TPE:1737) Seems To Use Debt Quite Sensibly

Returns On Capital - An Important Metric For Taiyen Biotech (TPE:1737)

A Look At The Fair Value Of Taiyen Biotech Co., Ltd. (TPE:1737)

How Much Of Taiyen Biotech Co., Ltd. (TPE:1737) Do Institutions Own?

Shareholders Of Taiyen Biotech (TPE:1737) Must Be Happy With Their 53% Return

Third quarter 2020 earnings released: EPS NT$0.48

New 90-day high: NT$32.70

New 90-day low - NT$30.60

First half earnings released